Tilray | TRLY - Current Liabilities


Tilray reported $259.32M in Current Liabilities for its fiscal quarter ending in September of 2025.





Current Liabilities Change Date
Acasti Pharma USD 1.28M 39K Dec/2025
Akebia Therapeutics USD 160.86M 13.02M Jun/2026
Alaunos Therapeutics USD 595K 218K Mar/2026
Aurora Cannabis CAD 66.93M 79M Mar/2026
Avita Medical AUD 62.68M 77K Dec/2025
Canopy Growth CAD 158.44M 60.15M Mar/2026
Cronos Group USD 56.36M 13.94M Jun/2026
Dianthus Therapeutics USD 34.39M 3.89M Jun/2026
Divis Laboratories Ltd INR 20.43B 3.15B Mar/2026
Ionis Pharmaceuticals USD 315.64M 401.36M Jun/2026
IQVIA Holdings USD 8.82B 486M Jun/2026
Knight Therapeutics CAD 165.26M 12.58M Dec/2025
Moderna USD 2.53B 139M Jun/2026
Organigram Holdings CAD 88.74M 5.31M Mar/2026
Organon & Co USD 2.62B 116M Jun/2026
Revvity USD 1.28B 37.71M Jun/2026
Tectonic Therapeutic USD 12.96M 3.29M Mar/2026
Tilray USD 259.32M 8.32M Sep/2025
Viatris USD 6.35B 464.5M Jun/2026
Xeris Pharmaceuticals USD 189.57M 70.97M Jun/2026
Zealand Pharma A/S 404M 260.96M Mar/2026